References
- Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med. 1999;340(18):1398–1405.
- Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004;350(9):876–885.
- Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353(23):2462–2476.
- Péntek M, Lakatos PL, Oorsprong T, et al. Access to biologicals in Crohn's disease in ten European countries. World Journal of Gastroenterology. 2017;23(34):6294–6305.
- Lirhus SS, Hoivik ML, Moum B, et al. Regional differences in anti-TNF-α therapy and surgery in the treatment of inflammatory bowel disease patients: a Norwegian nationwide cohort study. Scand J Gastroenterol. 2018;53(8):952–957.
- Torres J, Bonovas S, Doherty G, et al. ECCO guidelines on therapeutics in Crohn's disease: medical treatment. J Crohns Colitis. 2020;14(1):4–22.
- Harbord M, Eliakim R, Bettenworth D, et al. Third European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohns Colitis. 2017;11(7):769–784.
- D'Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet. 2008;371(9613):660–667.
- Colombel JF, Rutgeerts P, Reinisch W, et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology. 2011;141(4):1194–1201.
- Marchetti M, Liberato NL, Di Sabatino A, et al. Cost-effectiveness analysis of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease. Eur J Health Econ. 2013;14(6):853–861.
- Baji P, Gulácsi L, Brodszky V, et al. Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe. United European Gastroenterol J. 2018;6(2):310–321.
- Dutta B, Huys I, Vulto AG, et al. Identifying key benefits in european off-patent biologics and biosimilar markets: it is not only about price! BioDrugs. 2020;34:159–170.
- Lirhus SS, Høivik ML, Moum B, et al. Incidence and prevalence of inflammatory bowel disease in Norway and the impact of different case definitions: a nationwide registry study. Clin Epidemiol. 2021;13:287–294.
- Sykehusinnkjøp HF. Pharmaceutical strategy of the Norwegian hospital procurement trust. 2020. [updated 2020 Feb 19 02; cited 2020 Jul 10]. Available from: https://sykehusinnkjop.no/pharmaceutical-strategy-of-the-norwegian-hospital-procurement-trust-sykehusinnkjop-hf-
- Alulis S, Vadstrup K, Borsi A, et al. Treatment patterns for biologics in ulcerative colitis and Crohn's disease: a Danish Nationwide Register Study from 2003 to 2015. Scand J Gastroenterol. 2020;55(3):265–271.
- Burisch J, Pedersen N, Cukovic-Cavka S, et al. Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort. Inflamm Bowel Dis. 2014;20(1):36–46.
- Patil SA, Rustgi A, Langenberg P, et al. Comparative effectiveness of anti-TNF agents for Crohn's disease in a tertiary referral IBD practice. Dig Dis Sci. 2013;58(1):209–215.
- Armuzzi A, DiBonaventura MD, Tarallo M, et al. Treatment patterns among patients with moderate-to-severe ulcerative colitis in the United States and Europe. PloS One. 2020;15(1):e0227914.
- Panaccione R, Colombel J-F, Travis S, et al. Tight control for Crohn's disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial. Gut. 2020;69(4):658–664.
- Jorgensen KK, Olsen IC, Goll GL, et al. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 2017;389(10086):2304–2316.
- Buer LC, Moum BA, Cvancarova M, et al. Switching from Remicade® to Remsima® is well tolerated and feasible: a prospective, open-label study. J Crohns Colitis. 2017;11(3):297–304.
- Dylst P, Vulto A, Simoens S. Barriers to the uptake of biosimilars and possible solutions: a belgian case study. Pharmacoeconomics. 2014;32(7):681–691.
- Jakobsson GL, Sternegård E, Olén O, et al. Validating inflammatory bowel disease (IBD) in the Swedish National Patient Register and the Swedish Quality Register for IBD (SWIBREG). Scand J Gastroenterol. 2017;52(2):216–221.
- Lo B, Vind I, Vester-Andersen MK, et al. Validation of ulcerative colitis and Crohn's disease and their phenotypes in the Danish National Patient Registry using a population-based cohort. Scand J Gastroenterol. 2020;55(10):1171–1175.